<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494868</url>
  </required_header>
  <id_info>
    <org_study_id>16-009567</org_study_id>
    <nct_id>NCT03494868</nct_id>
  </id_info>
  <brief_title>Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity</brief_title>
  <official_title>Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative fasting and surgery can cause metabolic stress and insulin resistance. Oral&#xD;
      carbohydrate loading has been shown to attenuate the development of insulin resistance in the&#xD;
      non-pregnant population undergoing many different types of surgery. Pregnant women have an&#xD;
      increase in insulin resistance and therefore may further benefit from a preoperative&#xD;
      carbohydrate load prior to cesarean delivery. Although woman in the UK receive a carbohydrate&#xD;
      drink prior to elective cesarean delivery, the metabolic effects of these drinks on the&#xD;
      mother and neonate have not been evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    need additional funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>glucose, insulin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Fasting prior to elective cesarean section delivery (standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate Drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate Drink</intervention_name>
    <description>2 - 12 oz drinks</description>
    <arm_group_label>Carbohydrate Drink</arm_group_label>
    <other_name>Clearfast Preop Drink</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  ASA physical status II-III women presenting for scheduled, elective cesarean delivery&#xD;
             under neuraxial anesthesia&#xD;
&#xD;
          -  Singleton gestation at term (37-42 weeks)&#xD;
&#xD;
          -  Ages 18-50&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Preexisting diabetes (Gestational diabetes, Type I DM, Type II DM)&#xD;
&#xD;
          -  Taking insulin-sensitizing or other medications known to influence glucose or fatty&#xD;
             acid metabolism.&#xD;
&#xD;
          -  Kidney, heart, or liver disease. Severe lipid disorders.&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Pre-pregnancy BMI &gt;40&#xD;
&#xD;
          -  Prolonged period of time (&gt;4 hours) between ingestion of carbohydrate drink and&#xD;
             surgery&#xD;
&#xD;
          -  Four or more repeat cesarean sections&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily E Sharpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emily E. Sharpe, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

